Lahore: Citi Pharma Limited held a significant board meeting on October 29, 2024, in Lahore, aimed at reviewing the quarterly financial results for the period ended September 30, 2024. The meeting discussions were conducted both in-person and via Zoom, reflecting the hybrid operational modalities that have become prevalent in business governance.

The board's agenda focused on scrutinizing the financial performance of the company and its subsidiaries during the third quarter of 2024. The meeting was essential for laying down future strategies and ensuring compliance with financial regulations. This review is a part of the company's commitment to transparency and accountability in its financial disclosures.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma Limited has been diligent in communicating its financial standings to TRE Certificate Holders, who are informed accordingly about the company’s financial health and strategic directions.

The details of the financial results discussed in the meeting are expected to be released publicly through PUCARS, a regulatory filing system, within the specified timeframe. This ensures that all stakeholders, including investors and regulatory bodies, are well-informed about the company’s financial trajectory and operational outcomes.

Citi Pharma Limited continues to emphasize the importance of regular and thorough financial assessments to adapt to the dynamic economic environment and maintain its competitive edge in the pharmaceutical industry.